Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism

What Was Tested

The paper reports a study of Octreotide and Somatostatin in the context of hyperparathyroidism, published as a randomized controlled trial.

SRIF-receptor autoradiography was performed in parathyroid tissue samples.

Baseline values revealed a constellation of biochemical parameters typically found in pHPT.

Who Took Part

The abstract describes 40 patients taking part.

PubMed indexes the participants as teenagers, adults, middle-aged adults and older adults, both men and women.

In a controlled, prospective, triple-blinded, randomized clinical trial, the somatostatin analogue octreotide (SMS 201-995, Sandostatin) was evaluated in 40 patients with well documented pHPT.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The patients were allocated by chance, so the Octreotide group and the comparison group should start out alike.

Some patients received a placebo instead of Octreotide, giving a reference point.

What Was Measured

The subject headings attached to it are Autoradiography, Calcitonin, Calcium, Hormones, Hyperparathyroidism, Multivariate Analysis and Octreotide.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Octreotide and Somatostatin in 40 patients in people with hyperparathyroidism.

The publication is from 1995 (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association), a journal based in Germany.

More context: the Octreotide compound page and the Somatostatin compound page, Hyperparathyroidism research.